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Abstract Vanadium is a metal present in air pollution. Its
compounds may have both anticancer and carcinogenic prop-
erties. Vanadium compounds are tested in treatment of diabe-
tes and cancer. An important research direction aimed at better
understanding of the mechanisms of action of the vanadium
compounds is a more detailed insight into their impact on
inflammatory reactions. The aim of this study was to examine
the effect of micromolar concentrations of sodium
orthovanadate, Na3VO4, on the activity and expression of
cyclooxygenases: COX-1 and COX-2. PMA-activated THP-
1 macrophages were incubated in vitro for 48 h with micro-
molar concentrations of sodium orthovanadate. As shown by
an ELISA assay, sodium orthovanadate increases the quantity
of prostaglandin E2 being released into the medium in a dose-
dependent manner as well as impacts the quantity of the stable
metabolite of thromboxane A2: thromboxane B2. The use of a
COX-2 inhibitor, NS-398, revealed that this effect was inde-
pendent of changes in the activity of COX-2. Western blotting
analysis showed that sodium orthovanadate increased the
expression of COX-2 when used with NS-398. Quantitative
real-time PCR measurements of mRNA levels of genes
PTGS1 and PTGS2 revealed no effect of the tested vanadium
compound on the levels of analyzed transcripts.
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AP-1 Activator protein 1
BMOV Bis(maltolato)oxovanadium(IV)
CBP cAMP response element
CREB cAMP response element-binding protein
COX-1 Cyclooxygenase-1
COX-2 Cyclooxygenase-2
cPLA2 Cytosolic phospholipase A2
EP2 Prostaglandin E2 receptor-2
EP4 Prostaglandin E2 receptor-4
GLUT-4 Glucose transporter type 4
HUVEC Human umbilical vein endothelial cells
Na3VO4 Sodium orthovanadate
Nrf2 Nuclear factor erythroid 2-related factor-2
NSAID Nonsteroidal anti-inflammatory drugs
PGE2 Prostaglandin E2
PKA Protein kinase A
PMA Phorbol myristate acetate
PPARγ Peroxisome proliferator-activated receptor-γ
PTP Protein tyrosine phosphatase




Vanadium is a metal present in the polluted air in large urban
and industrial agglomerations. Environmental sources of va-
nadium include soil and pollution from combustion of fossil
fuels [1]. Prolonged exposure to vanadium oxide contained in
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the air may cause lung cancers [2]. Also, other inorganic
vanadium compounds are known to have carcinogenic prop-
erties. The mechanism of action of these compounds has been
well studied and proceeds along multiple pathways.
Vanadium compounds stimulate proliferation of cells while
simultaneously interfering with the course of apoptosis [3].
However, in vitro studies also revealed that the treatment of
cancer cells with vanadium compounds caused apoptosis and
inhibition of proliferation [4, 5]. Depending on the expression
of p53, vanadium compounds have either carcinogenic or
anticancer properties [3].
Molecular mechanisms of action of vanadium compounds
are still being studied. Thanks to the easily occurring changes
in their oxidation states, vanadium compounds generate reac-
tive oxygen species (ROS) by means of Fenton’s reaction or a
reaction with oxygen [6]. In addition, compounds in question
are structurally similar to phosphate anions. Thus, they may
act as protein tyrosine phosphatase (PTP) inhibitors [7]. As a
result of inhibition of these enzymes, numerous signaling
pathways are activated within cells.
Vanadium compounds are tested in experimental treatment of
diabetes as they inhibit PTP1B, among their other effects [8]. In
type 2 diabetes, the activity of this phosphatase is increased,
leading to insulin resistance. In addition, vanadium compounds
enhance the glucose transport mediated by glucose transporter
type 4 (GLUT-4) and the glycogen synthesis, leading to reduced
blood glucose levels [9]. However, due to the higher toxicity of
inorganic vanadium compounds, organic vanadium derivatives
such as bis(maltolato)oxovanadium(IV) (BMOV) are being test-
ed for their potential use in antidiabetic treatment [10].
An important research direction aimed at better understand-
ing of the mechanisms of action of the vanadium compounds
is a more detailed insight into their impact on inflammatory
reactions. These reactions are associated with numerous dis-
orders. They are important in the course of cancers or athero-
sclerosis. One of the most important inflammatory processes
is the synthesis of prostaglandins and thromboxanes, occur-
ring along cyclooxygenase pathway from arachidonic acid
released frommembrane phospholipids by means of cytosolic
phospholipase A2 (cPLA2). In physiological conditions,
cyclooxygenase-1 (COX-1) plays an important role in the
synthesis of prostaglandin E2 (PGE2). The expression of this
enzyme is maintained at the constitutive level and is rarely
changed. Expression of cyclooxygenase-2 (COX-2) is in-
creased in inflammatory reactions. Increased enzyme levels
lead to increased production of prostaglandins.
Increased expression of COX-2 in tumor cells is very im-
portant for the natural history of the disease. PGE2 being
synthesized by this enzyme disturbs apoptosis and promotes
angiogenesis, thus promoting tumor growth [11]. Potential
anticancer drugs should be examined for their effects on ex-
pression and activity of COX-2 and induction of inflammatory
reactions, as this would allow for development of safe therapies.
Considering the above, the aim of this study was to dem-
onstrate the effect of micromolar concentrations of sodium
orthovanadate on the development of inflammation in THP-1
macrophage cells by measuring the activity and expression of
COX-1 and COX-2 (at both mRNA and protein levels).
Material and Methods
Cell Culture
The study was conducted on macrophages obtained from a
monocytic line THP-1. Human THP-1 monocytic cells have
been widely employed as an in vitro model for investigating
the molecular mechanisms underlying monocyte-to-
macrophage differentiation [12]. THP-1 cells (ATCC,
Rockville, USA) were differentiated into macrophages by
administering phorbol myristate acetate (PMA) [12, 13] and
cultured in RPMI-1640 medium (BIOMED-LUBIN, Poland)
supplemented with 10 % FBS without fatty acid (ALAB,
Poland), penicillin (100 U/mL), and streptomycin (100 mg/
mL; Sigma-Aldrich, Poland) at 37 °C in 5 % CO2. The THP-1
monocytes were treated with 100 nM PMA (Sigma-Aldrich,
Poland) for 24 h, and then the adherent macrophages were
washed three times with PBS (BIOMED-LUBLIN, Poland)
and incubated with sodium orthovanadate (Na3VO4) (Sigma-
Aldrich, Poland) solution with or without specific COX-2
inhibitor NS-398 (Sigma-Aldrich, Poland) at final concentra-
tion of 50 μM for 48 h at 37 °C. Incubation time was selected
on the basis of results obtained in preliminary experiments.
Sodium orthovanadate was used at final concentrations of
80 nM, 1, 4, and 10 μM. These concentrations were selected
on the basis of in vitro study of cancer cells [5] and study on
blood vanadium concentration in Taiwanese students [14].
After incubation, cells were harvested by scraping and a pellet
was obtained by centrifugation (250g for 5 min).
The cell count was determined with a Bright Line
Hemacytometer (Sigma-Aldrich, Poznan, Poland). Cell via-
bility was examined using a trypan blue dye exclusion meth-
od. Cell cultures with viability more than 97 % were used for
experiments [15]. Protein concentration was measured by the
Bradford method [16].
Measurements of COX-1 and COX-2 Activity
Cyclooxygenases COX-1 and COX-2 activity were measured
in vitro by quantitative measurement of their products: PGE2 and
thromboxane A2 (TXA2). The cells were incubated for 48 h with
sodium orthovanadate solutions, as described above. PGE2 and
TXA2 were extracted from the culture supernatants with the use
of Bakerbond SPE columns (J.T. Baker, USA), as described in
manufacturer’s instructions. The concentrations of PGE2 released
were measured spectrophotometrically by using the PGE2
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enzyme immunoassay kit (Cayman Chemical, USA) according
to the manufacturer’s protocol. As TXA2 has a short half-life
(37 s) and is rapidly hydrolyzed nonenzymatically to its stable
derivative thromboxane B2 (TXB2), the thromboxane B2 en-
zyme immunoassay kit (Cayman Chemical, USA) was used to
measure free TXA2 indirectly.
Western Blotting Analysis of COX-1 and COX-2 Expression
Cells after incubation with sodium orthovanadate were washed
with PBS. After scraping, they were lysed with lysing buffer
containing protease inhibitor, ethylene-diaminetetra-acetic acid
5 mM, sodium dichloroisocyanurate 1 %, TRITON-X 1 %,
sodium orthovanadate 100 mM (Sigma-Aldrich, Poland), and
equal amounts of protein were separated in gel electrophoresis
and transferred to a nitrocellulose membrane (Thermo Scientific,
Pierce Biotechnology, USA) at 157 mA for 2 h at room temper-
ature. After blocking the membrane with 5 % non-fat milk in
Tris-buffered saline (Sigma-Aldrich, Poland) containing 0.1 %
Tween 20 (Sigma-Aldrich, Poland) for all night at 4 °C, it was
incubated with primary monoclonal antibodies direct against
COX-1 or COX-2 (Santa Cruz Biotechnology, USA) in dilution
1:200 with a monoclonal anti-ß-actin (1:5000; Santa Cruz
Biotechnology, USA) and next with secondary antibodies (goat
anti-mouse IgG HRP; Santa Cruz Biotechnology, USA) in dilu-
tion 1:5000. Signals were visualized by chemiluminescence
(Thermo Scientific, Pierce Biotechnology, USA). ImageJ 1.41o
(NIH, USA) was used to densitometric analysis of bands.
Imaging of COX-1 and COX-2 Immunoexpression
Expression of COX-1 and COX-2 proteins was examined
with confocal microscopy. THP-1 cells were grown on cover
glasses in standard in vitro culture conditions. Further, cells
were washed with PBS and fixed with 4 % buffered formalin
for 15 min in room temperature. After the fixation and wash-
ing with PBS, cells were permeabilized with 0.5 % solution of
Triton X-100 in PBS. After washing with fresh portion of
PBS, cells were incubated with mouse anti-COX-1 or anti-
COX-2 primary antibodies (Santa Cruz Biotechnology, USA)
in dilution 1:50, in 4 °C, overnight, and then washed and
incubated with secondary antibody: anti mouse IgG FITC
conjugated (Sigma-Aldrich, Poland) in dilution 1:60 in anti-
body diluent (Dako, Poland), 30min in room temperature, and
after washing with PBS further with Hoechst 33258, 30 min,
room temperature. The cells were examined under a confocal
microscope (FV1000 confocal with IX81 inverted micro-
scope, Olympus, Germany), three channel acquisition and
sequential scanning was used for best resolution of signal
from Hoechst 33258 and FITC fluorescence. Additionally,
fluorescent images were merged with transition light images.
Quantitative Real-Time PCR Analysis (qRT-PCR) of COX-1
and COX-2 mRNA
Quantitative mRNA expression of PTGS1 (NCBI Reference
Sequence: NM_000962) and PTGS2 (NM_000963) genes
was performed in a two-step reverse transcription PCR.
Total RNAwas extracted from cells using RiboPure kit (Life
Technologies, USA). After determination of the quantity and
quality of isolated RNA using a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies, USA), complementary
DNA (cDNA) was prepared using RevertAid First Strand
cDNA Synthesis kit (Fermentas, Thermo Scientiic,
Lithuania). Quantitative real-time PCR was performed in
7500 Fast Real-Time PCR System (Applied Biosystems,
USA), using pre-validated Taqman Gene Expression Assays
TaqMan GE Master Mix (Applied Biosystems, USA) and
1.5 μl of cDNA for each reaction mix of 15 μl. Each sample
was analyzed in two technical replicates, and mean CT values
were used for further analysis. Calculations were performed
using the ΔΔCt relative quantification method, using 7500
Fast Real-Time PCR System Software (Applied Biosystems,
USA). The thresholds were set manually to compare data
between runs, and CT values were extracted. All CT values
for each sample were normalized to the value obtained for
GAPDH and HPRT1, the endogenous control gene. Fold
change between groups was calculated from the means of
the logarithmic expression values.
Statistical Analysis
Arithmetical means and the standard deviations (±SD) were
calculated for each of the studied quantitative parameters. The
distribution of results for individual variables was obtained by
Shapiro-Wilk W test. As most of the distributions deviated
from normal distribution, non-parametric tests were used for
further analyses. To assess the differences between the used
concentration of vanadium, non-parametric Wilcoxon
matched pairs test and Friedmann’s ANOVAwere used. The
obtained results were analyzed statistically using Statistica 10
(StatSoft, Poland) software, and p values of less than 0.05
were considered as significant.
Results
COX-1 is the Main Source of Proinflammatory Factors
After Sodium Orthovanadate Treatment
Sodium orthovanadate added to the macrophages increased
PGE2 synthesis in a dose-dependent manner; however, the
significant results were obtained only for 10 μM vanadium
solution (Fig. 1).
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Similar results were obtained for measurement of
TXB2 concentration in cell cultures depending on the
cultivation conditions, but in such case, sodium
orthovanadate addition to the cells cause no changes
in TXA2 synthesis (Fig. 2).
The addition of NS-398—the selective COX-2 inhibitor to
the macrophage culture with sodium orthovanadate caused a
reduction of PGE2 and increase of TXB2 concentration vs.
cultures without inhibitor, but there were no significant differ-
ences against TXB2 result for 80 nM sodium orthovanadate
(p=0.02). Additionally, the increase in sodium orthovanadate
concentration was followed by an increase in PGE2 synthesis
(for 10 μM sodium orthovanadate p=0.04 compared to con-
trol) and TXA2 synthesis in macrophages.
The results show that orthovanadate at concentrations used
increases the quantities of PGE2 being released by macro-
phage cells of the THP-1 line, but the process is independent
on the activity of COX-2.
Protein Expression of COX-1 Enzyme Decreased but COX-2
Enzyme Not Changed After Sodium Orthovanadate Addition
to the Cells
Sodium orthovanadate lead to a 10–15 % reduction in COX-1
protein expression in macrophages cultured without NS-398
(Figs. 3 and 4). Statistically significant differences compared to
control were observed for sodium orthovanadate at concentra-
tions of 80 nM (p=0.012), 1μM(p=0.04), and 4μM(p=0.012).
Addition of the NS-398 inhibitor and different concentra-
tions of sodium orthovanadate into the culture had no effect on
the expression of COX-1 protein in macrophages; however, a
growing trend could be observed in COX-1 protein expression
starting from sodium orthovanadate concentration of 4 μM.
The studied vanadium compound had no significant effect
on the expression of COX-2 protein in THP-1 cells when used
at any concentration; however, the addition of COX-2 inhib-
itor lead to a significant increase in expression that was
dependent on concentration of the vanadium compound
(Figs. 5 and 6). Statistically significant differences were ob-
served for sodium orthovanadate solutions at concentrations
of 4 μM (p=0.03; 250 % increase compared to control) and
10 μM (p=0.03; 400 % increase compared to control).
Sodium Orthovanadate Does Not Affect mRNA Expression
of COX-1 and COX-2 Enzymes
Sodium orthovanadate has no statistically significant effect on
the mRNA levels of COX-1 and COX-2 in THP-1 cells
incubated with or without NS-398.
Discussion
The Effect of Sodium Orthovanadate on the Activity
of COX-1 and COX-2
At concentrations used in the tests, the studied vanadium
compound increases the quantities of PGE2 released into the
medium by macrophages. This effect is dependent on vanadi-
um concentration. The addition of a specific COX-2 inhibitor,
NS-398, leads to a minor reduction in the amount of PGE2
being released. Sodium orthovanadate, as an inhibitor of PTP,
may increase the activity of COX-2 by phosphorylating tyro-
sine residues within its molecule against COX-1 protein [17].
However, no change in the growing trend in PGE2 release was
observed in our studies upon the use of a COX-2 inhibitor.
This shows that sodium orthovanadate at concentrations used
has no effect on the activity of COX-2.
The increased PGE2 release observed in our studies may be
due to an increase in the activity of cPLA2. cPLA2 acts as
another, besides COX-2, checkpoint in the synthesis of PGE2.
Fig. 2 The quantity of TXB2 depending on sodium orthovanadate and
NS-398. THP-1 macrophages were cultured with sodium orthovanadate
solutions for 48 h. After incubation, cells were scrapped and TXB2
concentration was measured by using spectrophotometric method (n=
5). #p<0.05, statistically significant as compared with the experiment
with NS-398 (Mann-Whitney U test)
Fig. 1 The quantity of PGE2 depending on sodium orthovanadate and NS-
398. THP-1 macrophages were cultured with sodium orthovanadate solu-
tions for 48 h. After incubation, cells were scrapped and PGE2 concentra-
tion was measured by using spectrophotometric method (n=5). *p<0.05,
statistically significant as compared with control (Wilcoxon test)
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By its activity, cPLA2 regulates the supply of arachidonic acid
for the entire cyclooxygenase and lipoxygenase synthetic
pathway. This hypothesis may find its confirmation in studies
conducted in leukemia U-937 and BL-60 cell lines, revealing
significant increase in the release of arachidonic acid in pres-
ence sodium vanadate at concentration of 20 μM [18].
In our studies, sodium orthovanadate had no effect on the
synthesis of TXB2 while the use of the inhibitor caused a
statistically insignificant increase in the level of the synthe-
sized compound. Probably, the inhibitor increased the avail-
ability of arachidonic acid for COX-1 molecules by inhibiting
the activity of COX-2. The obtained results also suggest that
COX-1 is the main enzyme responsible for thromboxane
synthesis.
The Effect of Sodium Orthovanadate on the Expression
of COX-1 and COX-2 Proteins
To date, few studies have been conducted on the effect of
vanadium compounds on the expression of COX-1. In our
studies, wewere the first to demonstrate a ca. 10%, significant
reduction in COX-1 expression by micromolar concentrations
of sodium orthovanadate. COX-1 is a constitutive enzyme
containing an Sp1-binding motif within the PGHS-1 promoter
and activator protein 1 (AP-1)-binding motif within intron 8
[19]. Nonetheless, it was demonstrated that at low
concentrations, sodium orthovanadate might, by its ef-
fect on AP-1 and Sp1, alter the expression of COX-1,
by activating the nuclear factor erythroid 2-related fac-
tor-2 (Nrf2), within ERK MAPK pathway [20]. Nrf2 is
a transcription factor responsible for the expression of
antioxidative and phase II detoxicative enzymes. The
expression of these enzymes leads to reduced cytoplas-
mic levels of ROS, thus inhibition activation of JNK
MAPK [21]. This may disturb the activity of AP-1 and
cause Sp1 degradation [22]. This in turn cancels out the
effect of ROS on increased COX-1 expression. At
higher concentrations, sodium orthovanadate activates
JNK MAPK and AP-1 [23, 24]. These processes cancel
out the effect of vanadium compounds on Nrf2. It is
probably for th is reason that 10 μM sodium
orthovanadate causes no reduction in COX-1 expression.
In our studies, sodium orthovanadate in the presence of the
inhibitor did not cause to changes in COX-1 protein expres-
sion. This might be due to the levels of 15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2) being reduced by the COX-2
inhibitor, thus leading to increased activation of AP-1 [25,
26]. This process canceled out the effect of increased expres-
sion of antioxidative enzymes.
Studies conducted by Hirai et al., (1997) in human umbil-
ical vein endothelial cells (HUVEC) showed that sodium
orthovanadate had no effect on COX-1 protein expression
Fig. 3 Effect of sodium
orthovanadate on COX-1 protein
and COX-1 mRNA expression.
Effect of vanadium solutions on a
COX-1 mRNA expression and b
COX-1 protein expression
(densitometric analysis of protein
normalized to β-actin); d
representative Western blot in
macrophages cultured with
sodium orthovanadate without
andwith NS-398 (c and e). THP-1
macrophages were cultured with
sodium orthovanadate solutions
for 48 h. After incubation, cells
were harvested by scraping and
mRNAwas measured by using
real-time PCR method (n=3) and
protein expression by using
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while simultaneously increasing the COX-1 mRNA levels
[27]. However, the tested vanadium compound in the cited
study caused such effect in an exposure time-dependent
manner.
In order to better understand the effect of sodium
orthovanadate in short-term (several days long) anticancer
therapy and long-term antidiabetic therapy, one should thor-
oughly examine the effect of this compound on the expression
of COX-1 protein depending on the exposure time.
In our studies, sodium orthovanadate had no significant
effect on the expression of COX-2 protein within macro-
phages cultured without the addition of the inhibitor.
However, studies conducted in non-small-cell lung carci-
noma A549 cells [27] and HUVEC cells [24] revealed an
increase in COX-2 protein expression, although sodium
orthovanadate levels used in these studies were much
higher than those used in our study [24, 27].
The use of a COX-2 inhibitor caused a significant increase
in COX-2 protein expression in our study. Regulation of
COX-2 protein expression is a complex process involving
positive and negative feedback loops [28]. The expression of
COX-2 is inhibited in an autocrine manner by 15d-PGJ2 [28].
Gilroy et al., (1999) and Inoue et al., (2000) demonstrated that the
use of a specific COX-2 inhibitor leads to inhibition in the
activity of COX-2 and thus to reduction in 15d-PGJ2 levels
[25, 28]. 15d-PGJ2 disturbs activation of NF-κB and its ability
to bind DNA [29]. Reduced levels of this prostanoid lead to
inactivation of the negative feedback loop acting on NF-κB, AP-
1, and cAMP response element-binding protein (CREB),
resulting in increased COX-2 expression [28–30]. These pro-
cesses may occur in a peroxisome proliferator-activated
receptor-γ (PPARγ)-dependent manner, as this receptor is pres-
ent in macrophages of the THP-1 cell line [31]. Activated
PPARγ disturbs activation of AP-1 by JNK MAPK and binds
Fig. 4 Imaging of COX-1 enzyme
by fluorescence microscopy in
macrophages cultured with sodium
orthovanadate. THP-1
macrophages were cultured with
sodium orthovanadate solutions for
48 h. The immunohistochemistry
was performed using specific
primary antibody, mouse anti-
COX-1 (the overnight incubation at
4 °C), and secondary antibodies
conjugated with fluorochrome -
anti-mouse IgG-FITC (incubation
for 45 min at room temperature).
The nuclei of cells were DAPI
stained. Image analysis was
performed with a fluorescent
microscope using filters 38 HE
GFP for green fluorescence and 49
DAPI for blue fluorescence
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the cAMP response element (CBP) [26]. Activation of NF-κB
caused by reduced 15d-PGJ2 levels may be intensified by the
studied vanadium compound, as it was demonstrated to activate
NF-κB already at the levels of 20 μM [32].
According to Murakami et al. (1997), regulation of COX-2
protein expression involves also a positive feedback loop [33].
PGE2, acting via its receptors prostaglandin E2 receptor-2
(EP2) and prostaglandin E2 receptor-4 (EP4), acts in an auto-
crine manner to increase cytoplasmic cAMP levels and thus
COX-2 protein expression [28, 33]. Increased cAMP levels
activate protein kinase A (PKA) which, by phosphorylating
CREB protein leads to an increased COX-2 expression [34].
CREB may be additionally activated by the transduction of
signal onto PI3K by activated EP4 receptor [35]. The same
receptor may also increase the stability of COX-2 mRNA by
activating p38 MAPK [36, 37].
Addition of a COX-2 inhibitor, by reducing the quantities
of PGE2 being released, reduces the cellular cAMP levels thus
reducing COX-2 protein expression. At the same time, sodium
orthovanadate, by inhibition of the activity of PTP, affects
activation of MAPK cascades, which in turn increase COX-
2 expression by means of AP-1 and CREB activation [38].
Combination of all of the above processes may lead to
increased expression of COX-2 protein in cells cultured with
a COX-2 inhibitor and sodium orthovanadate, as observed in
our study. This may be of importance in combination exper-
imental antidiabetic and anticancer therapy with the use of
vanadium and non-steroidal anti-inflammatory drugs
(NSAID), leading to increased COX-2 expression and en-
hancement of inflammatory processes.
The Effect of Sodium Orthovanadate on the mRNA levels
of COX-1 and COX-2
The studied vanadium compound had no effect on the mRNA
levels of COX-1 and COX-2; however, in the studies by Hirai
et al. (1997), 10 μM sodium orthovanadate caused an increase
in the COX-1 and COX-2 mRNA depending on the HUVEC
cell line incubation times [27]. The authors of the cited study
observed rapid increase in mRNA levels, reaching a peak
value after several hours and then returning to the baseline
values [27], which might explain the lack of changes observed
in the mRNA levels of COX-1 and COX-2 following 48 h of
incubation with sodium orthovanadate.
Fig. 5 Effect of sodium
orthovanadate on COX-2 protein
and COX-2 mRNA expression.
Effect of vanadium solutions on
a COX-2 mRNA expression and
b COX-2 protein expression
(densitometric analysis of protein
normalized to β-actin); d
representative Western blot in
macrophages cultured with
sodium orthovanadate without
andwith NS-398 (c and e). THP-1
macrophages were cultured with
sodium orthovanadate solutions
for 48 h. After incubation, cells
were harvested by scraping, and
mRNAwas measured by using
real-time PCR method (n=3) and
protein expression by using
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Medical Implications of the Obtained Results
The increase in the levels of PGE2 induced by sodium
orthovanadate treatment was observed. In addition,
orthovanadate combined with COX-2 inhibitor was
shown to increase the expression of COX-2. Due to
the fact that the increased activity of COX-2 promotes
tumor growth, NSAID may therefore be recommended
in adjuvant anticancer therapy [39, 40]. Despite the fact
that increased expression of COX-2 upon the use of the
inhibitor does not lead to an increase in the activity of
this enzyme, sodium orthovanadate combined with
NSAID may trigger cellular signaling pathways that
lead to the synthesis of other proinflammatory
compounds.
Understanding the mechanisms of vanadium compounds
would permit to reduce the side effects of treatments being
developed or question the use of the studied vanadium com-
pounds in therapy.
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